Abstract
In addition to its approved use for the treatment of patients with attention‐deficit hyperactivity disorder (ADHD), the selective norepinephrine reuptake inhibitor atomoxetine is sometimes used off‐label as an adjunctive therapy for patients with major depressive disorder. Bupropion, a norepinephrine/dopamine reuptake inhibitor approved for the treatment of depression, is also used off‐label for ADHD. Bupropion is a potent inhibitor of CYP2D6, the cytochrome P‐450 isoenzyme responsible for mediating the primary hydroxylation pathway of atomoxetine to its active metabolite 4‐hydroxy‐atomoxetine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
